StockData
Merit Medical Systems Inc logo

Merit Medical Systems Inc (MMSI) company profile

MMSINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/309% below fair value
$84.49−1.86 (-2.15%)

Close on Nov 17, 2026Market cap $5.06BP/E 31.8Yield –

About Merit Medical Systems

Surgical & Medical Instruments & Apparatus, SIC 3841

Merit Medical Systems, Inc. designs, develops, and manufactures medical devices used in interventional, diagnostic, and therapeutic procedures. The company operates through two primary segments: cardiovascular and endoscopy. Its cardiovascular offerings include catheters, guide wires, introducer sheaths, embolotherapy products, biopsy systems, fluid management tools, and spine intervention devices, along with contract manufacturing services for original equipment manufacturers. Its endoscopy segment provides pulmonary and gastrointestinal devices such as esophageal stents and dilation balloons. The company sells its products to hospitals, acute care facilities, and healthcare professionals, including physicians, technicians, and nurses.

Headquartered in South Jordan, Utah, the company operates eleven manufacturing facilities located in the United States, Mexico, Brazil, Ireland, France, the Netherlands, and Singapore. It maintains research and development operations in the United States, Ireland, and France. The company distributes its products worldwide through distribution centers in North America, South America, Europe, Africa, Asia, and Oceania, supported by direct sales teams and more than 500 distributors in China.

Summary of the business section of Merit Medical Systems's latest annual report, written by StockData.

Company profile

Company

Legal name
Merit Medical Systems Inc
Founded
1987
Headquarters
South Jordan, UT
Address
1600 West Merit Park Way 84095
Phone
(801) 253-1600
Website
merit.com
Employees
7,500, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Utah
Fiscal year ends
December 31
Auditor
DELOITTE & TOUCHE LLP, Salt Lake City, Utah

Stock & identifiers

Ticker
MMSI
Exchange
Nasdaq
IPO date
May 14, 1990
Shares outstanding
60M, Oct 27, 2026
Public float
$5.40B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
5-for-4, May 6, 2011; 4-for-3, Dec 3, 2003; 4-for-3, Aug 15, 2003; 5-for-4, Apr 12, 2002; 5-for-4, Aug 28, 2001; 3-for-2, Jul 16, 1991
SEC CIK
856982
CUSIP
589889104
ISIN
US5898891040
FIGI
BBG000C42VX0
Share class FIGI
BBG001S6KLT3
LEI
549300OYTY138SP2CE83
EIN
87-0447695

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martha Goldberg AronsonPresident and CEO, Director49,792
Brian G. LloydCHIEF LEGAL OFFICER, SECRETARY62,132
Sheri LewisEVP of Global Operations8,371
Michel J. VoigtCHIEF HUMAN RESOURCES OFFICER47,677
Neil W. PetersonCHIEF OPERATING OFFICER18,051
Christian Adam SmithChief Commercial Officer32,554
Raul Parra Jr.CFO AND TREASURER61,542
Thomas J. GundersonDirector60,741
F. Ann Ed.D. MillnerDirector38,000
Michael R. McDonnellDirector9,852
Lonny J. CarpenterDirector20,824
Lynne N. WardDirector11,266
Stephen C. EvansDirector10,266
Laura S. KaiserDirector13,352
Scott R. WardDirector3,457
Silvia M. PerezDirector8,040
Fred P. LampropoulosDirector1,126,457
David FloydDirector15,066

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Fred P.Lampropoulos
$13.76M$9.88M$4.18M$159$100
FY2025
Martha G.Aronson
$6.73M$7.07M$4.18M$159$100
FY2024$10.38M$16.38M$3.20M$174$99
FY2023$10.05M$9.80M$2.74M$137$86
FY2022$8.13M$12.09M$2.09M$127$80
FY2021$7.54M$10.69M$1.68M$112$115

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Martha G. Aronson
President and Chief Executive Officer
$251.39K$250.00K$6.23M––$6.73M–
Raul Parra
Chief Financial Officer and Treasurer
$630.00K–$3.58M$549.18K$58.10K$4.82M+52%
Neil W. Peterson
Chief Operating Officer
$630.00K–$2.87M$470.72K$157.78K$4.12M+31%
Brian G. Lloyd
Chief Legal Officer, Corporate Secretary
$630.00K–$3.22M$470.72K$115.62K$4.44M+43%
Michel J. Voigt
Chief Human Resources Officer
$449.22K–$2.51M$336.23K$31.35K$3.32M–
Fred P. Lampropoulos
Former Chair of the Board, CEO and President
$1.89M–$9.31M$1.88M$668.64K$13.76M+32%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 7,500 employees located in approximately 43 countries performing a variety of roles.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?